About Dabur Research Foundation
Data last updated: 20 December 2025
Dabur Research Foundation is a public not for profit company based in New Delhi, Delhi, India. It specialises in pharma contract r and d, a part of the broader pharmaceuticals sector. Incorporated on 24 December 1979, the company has been in operation for over 47 years.
Registered with ROC Delhi under CIN U73100DL1979PTC010092.
It is led by directors including Pradip Burman and Gaurav Chamaria.
Last AGM: 18 September 2025. Financial statements filed for year ended 31 March 2025. Office: 8/3 Asaf Ali Road, New Delhi, Delhi, India – 110002.
As per the financials filed for FY 2025, the company reported a revenue of ₹28.06 Cr, a growth of 34% compared to the previous year.
The company has a workforce of approximately 115 employees as per the latest available data.
The company is associated with 1 brand - Dabur Research.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website daburresearch.in.
-
Email**************
-
Telephone**************
-
Website**************
-
Social Media
-
Registered Address8/3 Asaf Ali Road, New Delhi, Delhi, India – 110002
-
IndustryPharma, Pharma Contract R&D
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
CIN History of Dabur Research Foundation
Dabur Research Foundation has one previous CIN (Corporate Identification Number): U73100DL1979PTC010092. The current CIN is U73100DL1979NPL010092, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U73100DL1979NPL010092 | Current |
| U73100DL1979PTC010092 | Previous |
Associated Brands with Dabur Research Foundation
Dabur Research Foundation operates one associated brand: Dabur Research. These brands represent Dabur Research Foundation's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Offers preclinical studies, toxicology, discovery services, and consulting for pharmaceutical development. | daburresearch.in |
Competitors & Alternatives of Dabur Research Foundation
Brands and companies operating in the same space as Dabur Research Foundation include PHAXIAM, Gubra, BioQual and 6 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
PHAXIAM
|
Antibacterial treatments using bacteriophages are developed for resistant infections. | Lyon, France, France | 2004 |
Gubra
|
Preclinical CRO services for NAFLD/NASH, diabetes, and obesity are provided. | Horsholm, Denmark, Denmark | 2008 |
BioQual
|
Contract research on infectious disease models is conducted. | Rockville, United States, United States | 1981 |
Tigermed
|
Drug development and preclinical services are provided by Tigermed. | Hangzhou, China, China | 2004 |
Gentronix
|
In-vitro and in-vivo genetic toxicology screening services are provided. | Alderley Edge, United Kingdom, United Kingdom | 1999 |
Aquila BioMedical
|
Preclinical services in immunology, regeneration, neuroscience, and histology are provided. | Edinburgh, United Kingdom, United Kingdom | 2011 |
GV Research Platform
|
A platform for research and drug development services is offered. | Hyderabad, India, India | 2020 |
Shanghai Semero Biotechnology
|
Diversified preclinical services for brain-related disorders are provided. | Shanghai, China, China | 2014 |
Headlands Research
|
Clinical research services are provided by Headlands Research globally. | San Francisco, United States, United States | 2018 |
Business Activity of Dabur Research Foundation
Dabur Research Foundation is engaged in the principal business activity of professional, scientific and technical, with detailed activities including scientific research and development.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| M | Professional, Scientific and Technical | M5 | Scientific research and development | ********* |
Board of Directors of Dabur Research Foundation
Dabur Research Foundation is currently managed by 5 directors, with 8 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Pradip Burman | Director | 24 Apr 1998 | 28 Years 2 Months | Current |
|
Gaurav Chamaria
Also directs:
Super Hoze Industries Private Limited, Milky Investment And Trading Company, Blackburrow Agritech Private Limited and 5 more
|
Director | 15 Dec 2023 | 2 Years 6 Months | Current |
|
Anand Chand Burman
Also directs:
H & B Stores Limited., Dabur Securities Private Limited, Asia Pacific Healthcare Advisors Llp and 5 more
|
Director | 25 Aug 1981 | 44 Years 10 Months | Current |
| Pritam Das Narang | Director | 20 Sep 1994 | 31 Years 9 Months | Current |
| Vivek Chand Burman | Director | 01 Apr 1999 | 27 Years 3 Months | Current |
Financials of Dabur Research Foundation FY 2025 filings available
Dabur Research Foundation reported revenue of ₹28.06 Cr (up 34% YoY) for FY 2025. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue from Operations | ***** | ***** | ***** | ***** | ***** |
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Other Income | ***** | ***** | ***** | ***** | ***** |
| Total Revenue | ***** | ***** | ***** | ***** | ***** |
| Expenses | |||||
| Total Expenses | ***** | ***** | ***** | ***** | ***** |
| Raw Material Cost | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory FG | ***** | ***** | ***** | ***** | ***** |
| Change in Inventory WIP | ***** | ***** | ***** | ***** | ***** |
| Purchase of Traded Goods | ***** | ***** | ***** | ***** | ***** |
| Employee Cost | ***** | ***** | ***** | ***** | ***** |
| Managerial Remuneration | ***** | ***** | ***** | ***** | ***** |
| Audit Fees | ***** | ***** | ***** | ***** | ***** |
| Insurance | ***** | ***** | ***** | ***** | ***** |
| Power & Fuel | ***** | ***** | ***** | ***** | ***** |
| Interest | ***** | ***** | ***** | ***** | ***** |
| Depreciation | ***** | ***** | ***** | ***** | ***** |
| Other Expenses | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| EBITDA (Operating Profit) | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| Exceptional Items | ***** | ***** | ***** | ***** | ***** |
| Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Exceptional & Extraordinary Items | ***** | ***** | ***** | ***** | ***** |
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Tax & Net Profit | |||||
| Tax Expense | ***** | ***** | ***** | ***** | ***** |
| Current Tax | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax | ***** | ***** | ***** | ***** | ***** |
| Profit from Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Tax on Discontinued Operations | ***** | ***** | ***** | ***** | ***** |
| Profit | ***** | ***** | ***** | ***** | ***** |
| Net Margin % | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Shareholders' Funds | |||||
| Total Shareholders' Funds | ***** | ***** | ***** | ***** | ***** |
| Equity Capital | ***** | ***** | ***** | ***** | ***** |
| Reserves & Surplus | ***** | ***** | ***** | ***** | ***** |
| Money Against Warrants | ***** | ***** | ***** | ***** | ***** |
| Other Equity | ***** | ***** | ***** | ***** | ***** |
| Non-Current Liabilities | |||||
| Total Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Liabilities | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Long-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Current Liabilities | |||||
| Total Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Borrowings | ***** | ***** | ***** | ***** | ***** |
| Trade Payables | ***** | ***** | ***** | ***** | ***** |
| Other Current Liabilities | ***** | ***** | ***** | ***** | ***** |
| Short-Term Provisions | ***** | ***** | ***** | ***** | ***** |
| Total Equity & Liabilities | ***** | ***** | ***** | ***** | ***** |
| Non-Current Assets | |||||
| Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Tangible Assets | ***** | ***** | ***** | ***** | ***** |
| Intangible Assets | ***** | ***** | ***** | ***** | ***** |
| Capital WIP | ***** | ***** | ***** | ***** | ***** |
| Intangibles Under Dev | ***** | ***** | ***** | ***** | ***** |
| Investments | ***** | ***** | ***** | ***** | ***** |
| Deferred Tax Assets | ***** | ***** | ***** | ***** | ***** |
| LT Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Non-Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Assets | |||||
| Current Assets | ***** | ***** | ***** | ***** | ***** |
| Current Investments | ***** | ***** | ***** | ***** | ***** |
| Inventories | ***** | ***** | ***** | ***** | ***** |
| Trade Receivables | ***** | ***** | ***** | ***** | ***** |
| Cash & Bank Balance | ***** | ***** | ***** | ***** | ***** |
| ST Loans & Advances | ***** | ***** | ***** | ***** | ***** |
| Other Current Assets | ***** | ***** | ***** | ***** | ***** |
| Total Assets | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Cash from Operating Activities (CFO) | |||||
| Profit Before Tax | ***** | ***** | ***** | ***** | ***** |
| Non-Cash Adjustments | ***** | ***** | ***** | ***** | ***** |
| + Interest Expense | ***** | ***** | ***** | ***** | ***** |
| + Depreciation | ***** | ***** | ***** | ***** | ***** |
| +/- Unrealized Forex | ***** | ***** | ***** | ***** | ***** |
| - Dividend Income | ***** | ***** | ***** | ***** | ***** |
| - Interest Income | ***** | ***** | ***** | ***** | ***** |
| +/- Other Non-Cash Items | ***** | ***** | ***** | ***** | ***** |
| Changes in Working Capital | ***** | ***** | ***** | ***** | ***** |
| +/- Inventory | ***** | ***** | ***** | ***** | ***** |
| +/- Debtors | ***** | ***** | ***** | ***** | ***** |
| +/- Creditors | ***** | ***** | ***** | ***** | ***** |
| Reconciliation Adjustments | ***** | ***** | ***** | ***** | ***** |
| Cash Generated from Operations | ***** | ***** | ***** | ***** | ***** |
| Income Taxes Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFO (Cash from Operations) | ***** | ***** | ***** | ***** | ***** |
| Cash from Investing Activities (CFI) | |||||
| Acquisitions & Disposals | ***** | ***** | ***** | ***** | ***** |
| Disposal of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Acquisition of Subsidiaries | ***** | ***** | ***** | ***** | ***** |
| Capex | ***** | ***** | ***** | ***** | ***** |
| Purchase of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Sale of Fixed Assets | ***** | ***** | ***** | ***** | ***** |
| Other Investing Cash Flows | ***** | ***** | ***** | ***** | ***** |
| Net CFI (Cash from Investing) | ***** | ***** | ***** | ***** | ***** |
| Cash from Financing Activities (CFF) | |||||
| Equity Issuance | ***** | ***** | ***** | ***** | ***** |
| Debt Raised | ***** | ***** | ***** | ***** | ***** |
| Debt Repaid | ***** | ***** | ***** | ***** | ***** |
| Dividends Paid | ***** | ***** | ***** | ***** | ***** |
| Interest Paid | ***** | ***** | ***** | ***** | ***** |
| Net CFF (Cash from Financing) | ***** | ***** | ***** | ***** | ***** |
| Net Cash Position | |||||
| Net Change in Cash (Pre-Forex) | ***** | ***** | ***** | ***** | ***** |
| Closing Cash & Equivalents | ***** | ***** | ***** | ***** | ***** |
| Metrics | ***** | ***** | ***** | ***** | ***** |
|---|---|---|---|---|---|
| Liquidity | |||||
| Current Ratio | ***** | ***** | ***** | ***** | ***** |
| Quick Ratio | ***** | ***** | ***** | ***** | ***** |
| Cash Ratio | ***** | ***** | ***** | ***** | ***** |
| Efficiency | |||||
| Inventory Days | ***** | ***** | ***** | ***** | ***** |
| Debtor Days | ***** | ***** | ***** | ***** | ***** |
| Creditor Days | ***** | ***** | ***** | ***** | ***** |
| Cash Conversion Cycle | ***** | ***** | ***** | ***** | ***** |
| Asset Turnover | ***** | ***** | ***** | ***** | ***** |
| Profitability | |||||
| Net Profit Margin % | ***** | ***** | ***** | ***** | ***** |
| Operating Margin % | ***** | ***** | ***** | ***** | ***** |
| ROE % | ***** | ***** | ***** | ***** | ***** |
| ROCE % | ***** | ***** | ***** | ***** | ***** |
| Net Worth Margin % | ***** | ***** | ***** | ***** | ***** |
| Growth | |||||
| Revenue Growth % | ***** | ***** | ***** | ***** | ***** |
| Leverage | |||||
| Equity Multiplier | ***** | ***** | ***** | ***** | ***** |
| Debt / EBITDA | ***** | ***** | ***** | ***** | ***** |
| Solvency | |||||
| D/E Ratio | ***** | ***** | ***** | ***** | ***** |
| ICR | ***** | ***** | ***** | ***** | ***** |
Consolidated Statements
Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.
Charges & Borrowings Dabur Research Foundation
Dabur Research Foundation does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Dabur Research Foundation
View historical data on people associated with Dabur Research Foundation, including employment history and EPFO contributions.
Employee Count & EPFO Data of Dabur Research Foundation
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Dabur Research Foundation
GSTIN & GST Filing Data of Dabur Research Foundation
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Dabur Research Foundation
Credit Ratings, Legal Cases & Regulatory Alerts of Dabur Research Foundation
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Dabur Research Foundation
MSME Payment Delays by Dabur Research Foundation
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Dabur Research Foundation
Subsidiaries & Group Companies of Dabur Research Foundation
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Dabur Research Foundation with ownership details.
MCA Filings & Documents of Dabur Research Foundation
MCA Filings & Documents of Dabur Research Foundation
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Dabur Research Foundation
Recent News on Dabur Research Foundation
Frequently Asked Questions about Dabur Research Foundation
Dabur Research Foundation is an active public not for profit company in the pharma sector based in New Delhi, Delhi, India. It was incorporated on 24 December 1979 (47+ years old) and is registered under CIN U73100DL1979NPL010092. The company has 115 employees.
Dabur Research Foundation reported revenue of ₹28.06 Cr for FY 2025 (up 34.00% YoY).
The current directors of Dabur Research Foundation are:
The primary industry of Dabur Research Foundation is pharma. The company specifically operates in pharma contract r and d. The company is currently active in this sector.
Dabur Research Foundation can be reached at the registered office: 83 Asaf Ali Road, New Delhi, Delhi, India – 110002, or through the website daburresearch.in.
The company has its registered office at 83 Asaf Ali Road, New Delhi, Delhi, India – 110002.